← Back to Clinical Trials
Recruiting NCT07271576

NCT07271576 Research on the Protective Effects of Phycocyanin Against Liver Fibrosis and Cirrhosis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07271576
Status Recruiting
Phase
Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Condition Liver Fibrosis
Study Type INTERVENTIONAL
Enrollment 10 participants
Start Date 2025-06-04
Primary Completion 2027-06-04

Trial Parameters

Condition Liver Fibrosis
Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 10
Sex ALL
Min Age 18 Years
Max Age 75 Years
Start Date 2025-06-04
Completion 2027-06-04
Interventions
phycocyaninMaltodextrin (Placebo)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This clinical trial aims to determine whether phycocyanin, a natural protein derived from spirulina, can help treat liver fibrosis or cirrhosis in adult patients. The main questions it aims to answer are: * Can phycocyanin reduce blood levels of liver enzymes (such as ALT and AST) that indicate liver damage? * Can phycocyanin improve liver stiffness as measured by ultrasound? Researchers will compare the phycocyanin intervention group with a control group that receives a placebo (a similar-looking maltodextrin supplement without active ingredients) to explore if phycocyanin is more effective in treating liver fibrosis/cirrhosis. Participants will: * Take one sachet of either phycocyanin or placebo daily for at least 4 weeks. * Attend regular clinic appointments (typically every 2-3 months) for routine monitoring of your liver condition, which will include blood and urine tests. * Provide blood and stool samples once before the treatment and once after the 4-week treatment period. * Undergo an ultrasound evaluation of liver stiffness. The study will last approximately 2 years, and the personal information of all patients will be kept strictly confidential.

Eligibility Criteria

Inclusion Criteria: * Adults between the ages of 18 and 75; * Patients diagnosed with liver fibrosis or cirrhosis; * Voluntary participation in this study and signing of an informed consent form; * No acute diseases or significantly worsening symptoms for at least 4 weeks prior to enrollment. Exclusion Criteria: * Presence of severe comorbidities; * Allergy to phycocyanin; * Patients with a history of severe mental illness that may affect treatment compliance.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology